Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity - Yamagishi, S; Ishibashi, Y; Ojima, A (Int J Cardiol, 2014)